Guanabenz hydrochloride
Based on 2 publication(s) in Google Scholar
Guanabenz hydrochloride is an orally active α-2-adrenoceptor agonist. Guanabenz hydrochloride has antihypertensive effect and antiparasitic activity. Guanabenz hydrochloride interferes ER stress-signalling and has protective effects in cardiac myocytes. Guanabenz hydrochloride also is used for the research of high blood pressure.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.94%
- CAS No.: 23113-43-1
- Formule: C8H9Cl3N4
- Masse moléculaire:267.55
-
Stockage:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
GPCR/G Protein Compound Library
HY-L006
-
Neuronal Signaling Compound Library
HY-L013
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
Drug Repurposing Compound Library
HY-L035
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Endoplasmic Reticulum Stress Compound Library
HY-L054
-
Orally Active Compound Library
HY-L061
-
Neurotransmitter Receptor Compound Library
HY-L062
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Antiparasitic Compound library
HY-L082
-
Anti-Obesity Compound Library
HY-L087
-
Rare Diseases Drug Library
HY-L102
-
Antidepressant Compound Library
HY-L108
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Off-patent Drug Library
HY-L141
-
Antihypertensive Compound Library
HY-L145
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Cysteine Targeted Covalent Library
HY-L153
-
Cysteine Targeted Covalent Fragment Library
HY-L154
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
RNA Binding Bioactive Compound Library
HY-L248
-
Lactylation Compound Library
HY-L249
Publications Citing Use of MedChemExpress (MCE) Guanabenz hydrochloride
MoreVoir tous les produits spécifiques à Isoform Parasite
MoreVoir tous les produits spécifiques à Isoform Adrenergic Receptor
More
Activité biologique
|
Toxoplasma |
Guanabenz hydrochloride (0.5-50 μM, 24 h) is treated with increasing concentrations for 24 hours not affect cell viability[1].
Guanabenz hydrochloride (0.5-50 μM, 24 h) alone not affects the UPR targets, neither on mRNA or protein level nor the phosphorylation status of eIF2a. Guanabenz also not induces GADD34 or the constitutively active form CReP[1].
Guanabenz hydrochloride (0.5-50 μM, 24 h) alone not induces ER stress in neonatal rat cardiomyocytes[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Neonatal rat cardiac myocytes (NRCM)
-
Concentration:0.5-50 μM
-
Incubation Time:24 h
-
Result:Did not affect cell survival.
-
Cell Line:Neonatal rat cardiac myocytes (NRCM)
-
Concentration:0.5-50 μM
-
Incubation Time:24 h
-
Result:Increased the levels of low panel concentration-dependent UPR targets proteins.
-
Cell Line:Neonatal rat cardiac myocytes (NRCM)
-
Concentration:0.5-50 μM
-
Incubation Time:24 h
-
Result:Did not affect levels of UPR targets.
Guanabenz hydrochloride (5 mg /kg/d, i.p., oral; 10 mg/kg/d, gavage; for 3 weeks) reverses Toxoplasma-induced hyperactivity in latently infected mice[2].
Guanabenz hydrochloride (100 and 320 μg/kg and 1 mg/kg, i.v., over a period of 5 min at intervals of 40 min) reduces sympathetic outflow, heart rate and blood pressure in debuffered cats[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/cJ mice[2]
-
Dosage:5 mg/kg
-
Administration:5 mg/kg/day; i.p. ; for 3 weeks
-
Result:Reduced the latent brain cysts in both male and female BALB/cJ mice.
-
Animal Model:BALB/cJ mice[2]
-
Dosage:5 mg/kg; 10 mg/kg
-
Administration:5 mg /kg/d, i.p., oral; 10 mg/kg/d, gavage; for 3 weeks
-
Result:Reversed parasite-induced hyperactivity to near-baseline levels.
-
Animal Model:Cats[3]
-
Dosage:100 and 320 μg/kg and 1 mg/kg
-
Administration:100 and 320 μg/kg and 1 mg/kg, i.v., over a period of 5 min at intervals of 40 min
-
Result:Declined markedly blood pressure and nerve activity.
Chemical Information
-
CAS No. 23113-43-1
-
Appearance Solid
-
Masse moléculaire 267.55
-
Formule C8H9Cl3N4
-
Color White to off-white
-
SMILES
ClC1=C(/C=N/NC(N)=N)C(Cl)=CC=C1.Cl
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Cancer Lett
Repurposing the Neurokinin-1 receptor antagonist Aprepitant to eradicate relapsed/refractory acute lymphoblastic leukemia via mitochondria-driven necroptosis. [Abstract]2026 May 24:218621. PMID: 42184918 -
Brain Res Bull
The neuroprotective effect of guanabenz combined with α-lipoic acid in the hSOD1-G93A amyotrophic lateral sclerosis model. [Abstract]2026 Jun 1:239:111890. PMID: 41991114
Solvant et solubilité
DMSO : 100 mg/mL (373.77 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (9.34 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (9.34 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (279 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Christiane Neuber, et al. Guanabenz interferes with ER stress and exerts protective effects in cardiac myocytes. PLoS One. 2014 Jun 3;9(6):e98893. [Content Brief]
[2]. Jennifer Martynowicz, et al. Guanabenz Reverses a Key Behavioral Change Caused by Latent Toxoplasmosis in Mice by Reducing Neuroinflammation. mBio. 2019 Apr 30;10(2):e00381-19. [Content Brief]
[3]. T Baum, et al. Studies on the centrally mediated hypotensive activity of guanabenz. Eur J Pharmacol. 1976 May;37(1):31-44. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.7377 mL | 18.6883 mL | 37.3766 mL | 93.4415 mL |
| 5 mM | 0.7475 mL | 3.7377 mL | 7.4753 mL | 18.6883 mL | |
| 10 mM | 0.3738 mL | 1.8688 mL | 3.7377 mL | 9.3442 mL | |
| 15 mM | 0.2492 mL | 1.2459 mL | 2.4918 mL | 6.2294 mL | |
| 20 mM | 0.1869 mL | 0.9344 mL | 1.8688 mL | 4.6721 mL | |
| 25 mM | 0.1495 mL | 0.7475 mL | 1.4951 mL | 3.7377 mL | |
| 30 mM | 0.1246 mL | 0.6229 mL | 1.2459 mL | 3.1147 mL | |
| 40 mM | 0.0934 mL | 0.4672 mL | 0.9344 mL | 2.3360 mL | |
| 50 mM | 0.0748 mL | 0.3738 mL | 0.7475 mL | 1.8688 mL | |
| 60 mM | 0.0623 mL | 0.3115 mL | 0.6229 mL | 1.5574 mL | |
| 80 mM | 0.0467 mL | 0.2336 mL | 0.4672 mL | 1.1680 mL | |
| 100 mM | 0.0374 mL | 0.1869 mL | 0.3738 mL | 0.9344 mL |
Guanabenz hydrochloride Related Classifications
HY-12724A Related Classifications
Powered by Bioz